Wegovy is the brand name for a GLP-1 medication called Semaglutide. It was FDA-approved for obesity treatment in 2021.
In a placebo-controlled trial of adults without diabetes, those who received Wegovy lost an average of 15% of their initial body weight.
Saxenda is the brand name for the GLP-1 medication Liraglutide. It was FDA-approved in 2014 for weight loss.
In a 56-week study, 63.2% of patients taking Saxenda lost at least 5% of their body weight (compared with 27.1% in the placebo group who did the same).
Metformin is a generic medication that is FDA-approved for type II diabetes but sometimes used off-label for weight loss. It is generally more affordable for patients without insurance coverage. The cost of Metformin is included in your Sequence membership.
There are multiple studies exploring Metformin for weight loss and obesity treatment. One study from 2013 found Metformin to be effective for weight loss, particularly in those with insulin resistance. Similarly, other researchers have found Metformin to be effective for weight loss in patients with PCOS.
Your Sequence Clinician may determine that another medication or a combination of medications might work best for your medical history and biology. They will do a careful review of your specific case to ensure you’re getting an effective medication that meets your needs.
You can learn more about different medications, common side effects, and their results and costs, by visiting our blog.
By managing appetite, cravings, and blood sugar, GLP-1s help you maintain healthy habits. Prescription weight loss medications also give some members more energy and motivation.
*Based on 5,377 members who have been on the Sequence program for at least 26 weeks. Average reported body weight lost was 15.17% and the top quartile lost an average of 19.90% of body weight.